Morgantown, WV, United States
Morgantown, WV, United States

Time filter

Source Type

News Article | May 4, 2017
Site: www.prnewswire.com

MORGANTOWN, W.Va. and KALAMAZOO, Mich., May 4, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") and Proteos, Inc. ("Proteos") announced today that they have entered into a joint co-marketing agreement.  This mutual partnership allows Protea to combine Proteos' p...


Patent
Protea Biosciences Group | Date: 2012-06-25

Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R_(1 )is independently selected from (CH_(2))_(0-9)CH_(3), R_(2 )is selected from the group consisting of H and (CH_(2))_(0-5)CH_(3), Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.


Patent
Protea Biosciences Group | Date: 2012-06-25

Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R_(1 )is independently selected from (CH_(2))_(0-9)CH_(3), R_(2 )is selected from the group consisting of H and (CH_(2))_(0-5)CH_(3), Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.


Patent
Protea Biosciences Group | Date: 2014-06-23

A compound may generally comprise the formula: wherein R_(1 )is independently selected from C_(2)-C_(10 )alkyl or substituted alkyl, R_(2 )is independently selected from the group consisting of H and C_(1)-C_(6 )alkyl or substituted alkyl, X is selected from the group consisting of NH and O, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.


Patent
Protea Biosciences Group and George Washington University | Date: 2014-08-26

In various embodiments, a device may generally comprise a remote ablation chamber comprising an inlet and an outlet, a laser to deposit energy into a sample in the chamber to ablate the sample and generate ablation products in the chamber, a transport device in fluid communication with the outlet, an ionization source to ionize the ablation products to produce ions, and a mass spectrometer having an ion transfer inlet to capture the ions. The ablation products or the ions may be transported in a fluid stream from the ablation chamber through the transport device. The distance from the outlet of the ablation chamber to the ion transfer inlet may be from 1 cm to 10 m. Methods of making and using the same are also described.


News Article | November 10, 2016
Site: globenewswire.com

MORGANTOWN, W.Va., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced today that the Company has appointed David Halverson as its President. “We are pleased to announce the selection of David Halverson as President of Protea Biosciences,” stated Steve Turner, Protea’s Chairman & CEO. He added, “David has led the successful development of our proprietary molecular information services business. He is building a strong and growing customer base, which now includes major pharmaceutical and biotechnology companies; he is ideally suited to manage our business operations, as we position Protea to meet and lead the global demand for better molecular information, for improved pharmaceutical development.” David Halverson commented, “I am honored to be appointed to the position of President, as we continue to grow the company and add amazing new capabilities to our expanding portfolio of proprietary Metabolic, Proteomic, Biopharmaceutical, and Mass Spec Imaging workflows.  I have the highest confidence in our Company achieving the leadership position in the new molecular information services industry.” Prior to his appointment as President, Halverson served as Protea’s Vice President and Chief Business Officer. Before joining Protea, Halverson was employed by Huntingdon Life Sciences in various capacities, including Head of European and US Sales. He has over 20 years of management experience in the pharmaceutical services industry, including serving as a Director of Sales for PPD Discovery and the Quintiles Preclinical Groups. Protea Biosciences Group, Inc. (OTCQB:PRGB) is a leading molecular information company providing proprietary bio-analytical technology to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms. Protea is a registered trademark of Protea Biosciences Group, Inc.


News Article | January 18, 2017
Site: globenewswire.com

MORGANTOWN, W.Va., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today that the Company has signed a renewal of its collaboration with California-based Protein Metrics Inc. for further applications development of their advanced analytical software for Protea’s molecular information services. “By combining our high-resolution mass spectrometry molecular data with the analytical power of Protein Metrics software, we are delivering more comprehensive molecular information to researchers who are developing complex biotherapeutics,” commented David Halverson, Protea’s President and Chief Business Officer.  He added, “This collaboration will empower researchers with bioinformatics tools to facilitate the analysis of the structure of therapeutic proteins, including their disulfide linkages, glycoforms and other structural components.” Protea and Protein Metrics plan to create co-authored presentations this year to highlight the benefit of the combined analytical workflows with data processing and reporting capabilities. Eric Carlson, President and CEO of Protein Metrics, commented “We are delighted to renew our partnership with Protea Biosciences.  It’s exciting to contribute to the quality analysis and reports that Protea provides to their many clients.  Thanks to the input from Protea during the first stage of our collaboration, our latest releases include many new features that allow analysts to review all of their data on a common platform and share it with collaborators and customers in a clear, consistent fashion.” About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing proprietary, bioanalytical workflows to the pharmaceutical and life science industries. "Molecular information", the generation and bioinformatic processing of very large data sets, is obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. About Protein Metrics Inc. Protein Metrics has deep experience in protein identification software.  With its current software products and multiple new products to be released shortly, Protein Metrics delivers tools to increase productivity and analytical quality, reduce costs and accelerate development timelines. Protein Metrics is a dynamic software company serving biopharmaceutical development professionals and proteomics researchers. The Company focuses on the analysis of mass spectrometric and other analytical data to provide detailed, efficient characterization of proteins and glycans. Over the past ten+ years, hardware for mass spectrometry has improved dramatically, and the company’s aim is to allow researchers to convert the new wealth of data from these instruments into to knowledge by providing innovative software that makes analytical results more accurate, more complete, and easier to achieve.  The company is headquartered in San Carlos, California.  For more information, visit www.proteinmetrics.com. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. For more Information:          Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.292.7101 Details of Protein Metrics biopharma suite can be found at www.proteinmetrics.com Protea is a registered trademarks of Protea Biosciences Group, Inc.


News Article | January 10, 2017
Site: globenewswire.com

MORGANTOWN, W.Va., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today that the Company has entered into a co-marketing agreement with MatTek Corporation (“MatTek”), which allows Protea to include MatTek’s human cell based in vitro tissue models with Protea’s proprietary molecular imaging services. “By combining the human tissue models with mass spectrometry imaging workflows, researchers will be able to visualize specific compounds in highly - controlled experimental conditions using human cell derived, in vitro models,” stated Haddon Goodman, Vice President, Corporate Development.  He added, “For example, utilizing MatTek’s EpiDerm™ skin model, we can map the distribution of topical compounds, while also visualizing the distribution of biomolecules present in the tissue. These experiments determine if a compound is penetrating the skin without using a tag or marker on the compound, which are commonly needed for visualization using traditional techniques.” The in vitro models are easier to source, much more reproducible and more humane as compared to human or animal skin tissues. MatTek is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models.  The outstanding relevance and reproducibility of EpiDerm and EpiOcular, MatTek’s corneal tissue model, produced impressive results in international multi-laboratory pre-validation and validation studies, leading to acceptance by OECD as test methods for skin and ocular irritation and corrosion testing. The companies plan to jointly present data at the 76th annual Society for Investigative Dermatology conference on April 26-29 in Portland, Oregon.  This work will highlight the benefit of integrating human cell-based tissue models with Protea’s mass spectrometry imaging workflows. About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing proprietary, bioanalytical workflows to the pharmaceutical and life science industries. "Molecular information", the generation and bioinformatic processing of very large data sets, is obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. About MatTek Corporation:  MatTek Corporation is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models. MatTek’s skin, ocular, intestinal and respiratory tissue models are used in regulatory toxicology (OECD, EU guidelines) and product development programs to address toxicology and efficacy concerns throughout the cosmetic/personal care, household product, chemical, and pharmaceutical industries. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.


— The analysts forecast the global tissue diagnostics market to grow at a CAGR of 11.59% during the period 2016-2020. Tissue diagnostics involves the diagnosis of diseases or analysis of the biological causes of the disease by extracting and analyzing a specific tissue. It has a broad range of applications in clinical research, clinical diagnostics, and cell biology. It is considered one of the most accurate techniques for the diagnosis of inflammatory conditions. Medical specialists particularly use tissue diagnostics in the area of molecular biology for cancer screening, therapy selection, diagnosis, and relapse monitoring. It helps in the screening and diagnosis of lymphoma, melanoma, leukemia, and breast, ovarian, cervical, head and neck, pancreatic, non-small cell lung, colorectal, brain, prostate, lung, and endometrial cancers. Pathologists use different technologies such as in situ hybridization (ISH), immunohistochemistry (IHC), special staining, and digital pathology and related methods including core biopsy, fine needle aspiration cytology, and open biopsy to study and diagnose cells. For more information or any query mail at sales@wiseguyreports.com The report covers the present scenario and the growth prospects of the global tissue diagnostics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of diagnostic devices based on the following techniques: The market is divided int the following segments based on geography: • Americas • APAC • EMEA The report, Global Tissue Diagnostics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors • 20/20 GeneSystems • Abcam • AdnaGen • Advanced Cell Diagnostics • Affymetrix • Agendia • AutoGenomics • AVIVA BioSciences • Biocare Medical • Biocartis • Cancer Genetics • ELITechGroup • Enzo Biochem • Epic Sciences • Fluidigm • HORIBA Medical • Janssen Diagnostics • Olympus Diagnostics Systems Group • Omnyx (a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, US) • Oxford Gene Technology • PANAGENE • Protea Biosciences Group • Sakura Finetek Market driver • Implementation by new customers • For a full, detailed list, view our report Market challenge • Insurance coverage and reimbursement issues • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? PART 06: Reimbursement and coverage: An overview • Current scenario: Validating diagnostic tests • Reimbursement structure in US • Reimbursement structure in EU • Prevailing issues of reimbursement policies PART 08: Market segmentation by technology • Global tissue diagnostics market by advanced staining • Global tissue diagnostics market by digital pathology • Global tissue diagnostics market by preanalytical and routine staining PART 09: Market segmentation by product • Global tissue diagnostics market segmentation by consumables • Global tissue diagnostics market segmentation by instruments For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | October 19, 2016
Site: globenewswire.com

MORGANTOWN, W.Va., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today the use of the Company’s proprietary LAESI technology to provide rapid profiling of a bacteria’s resistance to antibiotics. The results were recently published in the International Edition of the Journal Angewandte Chemie, by Dr. H. Li, and Prof. Akos Vertes, Department of Chemistry, The George Washington University. The publication’s title is “Molecular Imaging of Growth, Metabolism, and Antibiotic Inhibition in Bacterial Colonies by Laser Ablation Electrospray Ionization Mass Spectrometry (LAESI).” “We are pleased to see the unique capabilities of LAESI technology applied to antibiotic research,” stated Steve Turner, Protea’s CEO. He added, “In this study, LAESI was shown to help reveal molecular information that has the potential to significantly contribute to new antibiotic research and development.” Professor Vertes commented, “With the emergence of multidrug resistant microbial strains and bacterial pathogens, the need for rapid and accurate testing of antibiotic susceptibility is increasing. Understanding microbial metabolism and its inhibition by antibiotics is important for developing new treatments of bacterial infections. These results indicate the potential of LAESI-MSI to study antibiotic diffusion patterns in tissues qualitatively and quantitatively, and to explore complex bacterial interactions.” Characterizing existing and emerging microbial strains and their interactions with antimicrobial agents currently relies on time-consuming methods with limited ability to provide molecular information. Assessing the metabolic adaptation of microbial colonies requires the capability to perform non-targeted molecular imaging in a native environment. LAESI technology enabled the direct analysis and imaging of numerous metabolites and lipids in both two and three dimensions. LAESI technology was invented in the laboratory of Professor Akos Vertes and exclusively licensed to Protea. LAESI is new bioanalytical technology that directly detects and maps molecules in diverse biological samples without the need to apply chemicals or introduce tags or tracers. LAESI enables both 2D and 3D molecular imaging, and results are available in seconds to minutes. About Protea Biosciences Group, Inc.:  Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. The company provides proprietary molecular information services to its clients in the pharmaceutical and life science industries. Forward-Looking Statements; This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. For more Information:   Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA Phone:  304.292.2226      Fax:  304.292.7101 Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

Loading Protea Biosciences Group collaborators
Loading Protea Biosciences Group collaborators